New Zealand markets closed

Telefônica Brasil S.A. (VIV)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
8.00-0.24 (-2.91%)
At close: 04:00PM EDT
8.00 0.00 (0.00%)
After hours: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close8.24
Open8.13
Bid0.00 x 4000
Ask0.00 x 2200
Day's range7.93 - 8.13
52-week range7.62 - 11.78
Volume1,107,790
Avg. volume1,133,903
Market cap13.63B
Beta (5Y monthly)0.07
PE ratio (TTM)12.70
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield0.14 (1.75%)
Ex-dividend date01 Sept 2022
1y target estN/A
  • Business Wire

    Avivagen Announces AGM Results and Update to Shareholders

    OTTAWA, Ontario, April 08, 2022--Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) ("Avivagen" or the "Company"), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, today announced the results of its annual general meeting of shareholders and highlighted the significant progress made in the Corporation’s efforts t

  • Business Wire

    Avivagen Inc. Announces Results for the First Quarter Ending January 31, 2022

    OTTAWA, Ontario, March 30, 2022--Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) ("Avivagen"), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, has announced its unaudited financial results for the first quarter of 2022.

  • Business Wire

    Avivagen Announces Closing of Private Placement of Debentures and Shares

    OTTAWA, Ontario, March 28, 2022--Avivagen Inc. (TSXV:VIV) ("Avivagen" or the "Company"), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, is pleased to announce that it has closed its previously announced private placement financing (the "Offering") of secured debentures (the "Debentures") for gross